Cell Notes: When iPSCs Start to Deliver: From Elegant Concept to Measurable Function — iPSCs Begin to Show What Translation Looks Like in Practice

In her monthly column "Cell Notes," AABB's Christina Celluzzi, PhD, MS, CABP(H), shares insights, findings and commentary on emerging topics in biotherapies. Subscribe to CellSource to receive "Cell Notes" and biotherapies updates from AABB directly in your inbox. 

There’s a point in science where possibility stops being the most interesting part. Not when something first works, but when it works often enough that you start to ask what to do with it. Induced pluripotent stem cells (iPSCs) feel like they’re arriving at that point. 

For years, iPSCs seemed almost too elegant not to matter. Take an adult cell and reprogram it back to a pluripotent state — essentially resetting its identity — and suddenly, you have something with almost unlimited potential. The idea was compelling and, for a long time, mostly theoretical. 

That’s changing. 

Nearly two decades after Shinya Yamanaka first described cellular reprogramming, iPSC-derived products are beginning to show up in the clinic in ways that feel real. In the treatment of Parkinson’s disease, transplanted dopaminergic progenitors have demonstrated survival and early functional signals in first-in-human studies, including evidence of engraftment, dopamine production and measurable improvements in motor function. Ongoing trials continue to refine how these cells are prepared, delivered and evaluated.  

What feels different now isn’t just activity, it’s that the signal is starting to hold.  

At the same time, iPSCs are proving their value beyond therapy. As disease models, they offer something we haven’t really had before: patient-specific biology in a controlled system. Cells can be derived from individuals with defined genetic and clinical profiles. They can then be studied under defined conditions, making it possible to observe how disease-related pathways behave and how they respond to potential therapies in ways that are more directly relevant to human biology.  

But as the field moves forward, the harder questions are becoming clearer. Reprogramming remains inherently variable. Differentiation isn’t always consistent. And at scale, small differences in process can translate into meaningful differences in cell identity and function. These are not just technical issues. They define what the product actually is at the time of use. Questions around genomic stability and tumorigenicity haven’t gone away. They’ve just become more precisely defined. 

So the focus is shifting again. Early on, the promise of iPSCs was personalization. Now, the pressure is on reproducibility. The field is moving toward banked, well-characterized cell lines – not because personalization isn’t valuable, but because consistency is what will make these therapies usable at scale. 

That’s the real inflection point. Not when the science works, but when it works well enough — and reliably enough — to use. And when it does, the questions start to change. 

Suggested Reading: